Liminatus Pharma, Inc. Class A Common Stock
Stock Chart, Company Information, and Scan Results
$4.61(as of Aug 25, 4:00 PM EST)
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Liminatus Pharma, Inc. Class A Common Stock Company Information, Fundamentals, and Technical Indicators
Stock Price$4.61
Ticker SymbolLIMN
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees1
CountyUSA
Market Cap$6.9M
EBIDTA-4.1M
P/E Ratio0.00
Forward P/E Ratio0.00
Earnings per Share-24.00
Profit Margin0.00%
RSI39.92
Shares Outstanding1.3M
ATR0.91
52-Week High179.99
Volume68,495
52-Week Low4.75
Book Value0.0M
P/B Ratio0.00
Upper Keltner7.71
P/S Ratio0.00
Lower Keltner3.60
Next Earnings Date10/02/2026
Cash Surplus0.0M
Next Ex-Dividend DateUnknown
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Join Our Free Email List
Get emails from us about ways to potentially make money in the stock market.